Shares of Jiangsu Hengrui Pharmaceuticals soared Friday morning, as more companies seek to tap Hong Kong’s capital markets.

Theodore Shou, CEO of Yiyi Capital, discusses the recent strong performance of the IPO market in Hong Kong and says that the valuation premium between mainland China and Hong Kong stocks would narrow ...

Singapore biotech firm Mirxes began trading in Hong Kong on May 23 at a valuation exceeding US$1 billion. Read more at ...

Company raises HK$9.89 billion (US$1.29 billion), with the proceeds to be used to support clinical trials and expand ...

The Chinese drugmaker raised HK$9.74 billion, equivalent to US$1.25 billion, in net proceeds, making it one of Hong Kong's largest IPOs so far this year. The stock was priced at HK$44.05 per share, ...

In response to Fitch maintaining Hong Kong's AA- credit rating and stable outlook, the Hong Kong Special Administrative ...

In related news, Singapore-based pharmaceutical company Mirxes, which specializes in cancer treatment, also had a strong debut in Hong Kong on the same day. The company’s shares rose by 28% in morning ...

Chinese pharmaceutical firm Jiangsu Hengrui had a storming first day of trading in Hong Kong on Friday, up 25.2 percent at closing -- a sign of hope for the city's prospects as a listing hub.

As a leading international institution ranked among the top universities globally, HKUST is extending this opportunity to ensure talented students can pursue their educational goals without disruption ...

The NYSE debut is the first major IPO for a venture-backed digital-health company since the pandemic-era boom. The top lender, advised by law firm Paul Weiss, is in discussions to take over the ...

Singapore-based cancer diagnostics firm MiRXES has listed on the Hong Kong Stock Exchange, with shares jumping 24.5% above the HKD 23.3 offer price on debut. The stock was trading at HKD 30 as of 3:00 ...

For years, Dominari Holdings’ shifting priorities and tribulations remained largely out of the spotlight. That changed when ...